AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 285 min read$GSK

GSK (GSK) Q3 2026 Earnings Call Transcript

GSK reported Q3 2026 earnings, highlighting progress in its oncology pipeline, including approvals for Jideytro, Hibsago, and Jemperli. The company discussed data on Jideytro and neladalkib for non-small cell lung cancer, Ris-Rez for various solid tumors, and Mo-Rez for ovarian cancer. GSK also mentioned its Accelerate Growth program to reallocate resources to R&D and accelerate late-stage development.

Original reporting
finance.yahoo.com
Published Oct 28, 2026, 9:58 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 10:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
GSK (GSK) Q3 2026 Earnings Call Transcript — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$GSKBullishMed
01

Why it matters

New efficacy data and accelerated approvals provide fresh catalysts that could affect GSK's stock and sector sentiment.

02

Market read

First‑report of detailed trial outcomes and approvals may drive GSK stock movement and influence oncology peers.

03

What to watch

Regulatory timelines and reimbursement negotiations could delay commercial impact.

Relevance 8/10Novelty 8/10Timing: post‑earnings call today

Background

The transcript is from GSK's Q3 2026 earnings call, focusing on oncology pipeline updates and recent FDA approvals.

Company-level read

Ticker impact

$GSKBullishHigh confidence
Context

GSK disclosed new clinical trial data, FDA approvals and pipeline progress for Jideytro, Hibsago, Jemperli and several ADC candidates.

Expected impact

likely upward pressure as investors price in potential new product revenue.

Evidence & confidence

First‑report of detailed efficacy numbers and accelerated approvals provides fresh material that can move the stock.

Market effects

Sector

Strengthens the broader pharma/oncology sector outlook with new late‑stage assets.

Regional

UK‑based GSK may benefit European biotech sentiment.

Global

Adds to global pipeline competition, especially in ROS1/ALK lung‑cancer space.

Counterpoint

What could challenge this read

If trial data fail to translate into approvals, the hype could reverse quickly.

Key entities

  • company
    GSK

    UK‑based pharmaceutical giant.

  • drug
    Jideytro

    ROS1‑targeted TKI with CNS activity.

  • drug
    Hibsago

    Finite treatment for chronic hepatitis B.

  • drug
    Jemperli

    Accelerated‑approval ADC for rectal cancer.

Read at source← All news

Also covered by

1 outlet

Related articles

OCT 28
$GSKHighAI 8/10

Glaxo: Q3 Earnings Snapshot

GSK reported Q3 net income of $2.07B, or $1.02 per share, beating analyst estimates of $1.40 per share. Adjusted EPS was $1.47. Revenue was $11.95B, exceeding forecasts of $11.8B.

finance.yahoo.com2 min
OCT 28
$GSKMedAI 8/10

What GSK (GSK) Said on Its Q3 Earnings Call

GSK reported Q3 earnings, highlighting growth in oncology drugs like Blenrep, Ojjaara, and Jemperli, and new approvals for Jideytro and Hibsago. Vaccine sales declined 2%, while meningitis portfolio rose 12%. GSK launched 18 phase III studies in 2026, with plans for more. Financials showed 7% gross profit increase, stable margins, and £1.8 billion free cash flow rise. The company expects £10 billion in cash from operations for the full year and core operating margin above 31%.

finance.yahoo.com2 min
OCT 28
$GSKMedAI 8/10

GSK Profit Falls Amid Cost-Saving Overhaul

GSK reported a 23% drop in Q3 net profit to £1.5B due to restructuring costs, but revenue rose 4% to £8.9B. The company reaffirmed its full-year guidance, with strong sales in cancer, respiratory, and HIV drugs. CEO Luke Miels emphasized long-term focus on R&D and operational delivery.

pharmacy.biz2 min
OCT 28
$GSKMedAI 8/10

GSK pipeline doubts, vaccine underperformance overshadow sales beat

GSK's shares fell 4% despite Q3 sales and profit beats, as investors focused on pipeline concerns and weak vaccine sales, including Shingrix. CEO Luke Miels emphasized long-term strategy and R&D focus. Specialty medicine sales rose 15%, but new asthma drug and vaccine revenue missed expectations. GSK maintained annual outlook but expects R&D spending to outpace sales growth. The company is restructuring to fund new medicines, with a £328 million restructuring charge in Q3.

finance.yahoo.com3 min
OCT 28
$WENHigh

Market movers: Stellantis, F5, Wendy's, GE

Wendy's shares rose 15% to $7.07 after a $7.35/share cash offer. Stellantis shares surged 15% on higher Q3 income and 2027 cash flow target. SK Hynix reported record Q3 revenue of $79B, up 328% YoY. Etsy's Q3 revenue rose 11%, shares up 3.8%. Vertiv raised 2026 forecasts after Q3 revenue beat estimates. GE Vernova's Q3 net income nearly tripled to $1.3B. NXP Semiconductors beat Q3 expectations but shares fell 2.2% on outlook. F5 shares dropped 18% on weaker guidance despite 13% revenue growth.

proactiveinvestors.com3 min